Skip to main content

Table 3 Association of NPAS2 rs6542993 with disease progression in advanced prostate cancer patients treated with ADT

From: Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression

Gene SNP Genotype No. of patients No. of events 5-year survival rate (%) P a HR (95% CI) P b
NPAS2 rs6542993 AA 126 109 17.9   1.00  
   AT 150 143 10.4   1.44 (1.09–1.90) 0.010
   TT 47 43 10.9   1.05 (0.73–1.53) 0.782
   AT/TT vs AA     0.024 1.32 (1.01–1.71) 0.039
   TT vs AA/AT     0.362 0.87 (0.62–1.22) 0.419
   Trend     0.284 1.09 (0.92–1.28) 0.339
  1. ADT, androgen-deprivation therapy; SNP, single nucleotide polymorphism; HR, hazard ratio; 95% CI, 95% confidence interval; PSA, prostate-specific antigen
  2. P < 0.05 are in italicsface
  3. aP values were calculated using the log-rank test
  4. bHRs were adjusted for age, PSA at ADT initiation, biopsy Gleason score, clinical stage, PSA nadir, and treatment modality